Seller record · Telehealth service

Vea Health

Fails 2 of 8 criteria. S5, analytical documentation: Product pages claim triple testing and batch purity, potency and sterility checks without providing a reachable certificate of analysis or lot document. 1 more criterion also fails; see the table below.

At a glance

Vea HealthTelehealth service

5/8criteria passed
Price
Not printed before a consultation or sign-up
Sells
compounded semaglutide, compounded tirzepatide, NAD+
FDA letters
None on file
Visit Vea HealthSee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1.

A telehealth platform combining clinician-reviewed compounded treatments with an included health-tracking app, with medical care supplied by a separate professional practice.

Operating entity Vea Health, Inc.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSVea Health's telehealth consent; Vea Health's semaglutide product page
S2Prescription gatingNOT VERIFIEDVea Health's semaglutide product page; Vea Health's terms and conditions
S3Pharmacy identificationPASSVea Health's telehealth consent
S4Compounding disclosurePASSVea Health's website; Vea Health's telehealth consent
S5Analytical documentationFAILVea Health's semaglutide product page; Vea Health's tirzepatide product page
S6Business addressPASSVea Health's privacy policy; Vea Health's telehealth consent
S7Price disclosureFAILVea Health's semaglutide product page; Vea Health's tirzepatide product page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSDr Telx, PLLC provides clinical care, and the product pages require a licensed clinician to review the request before a prescription is issued.Source: Vea Health's telehealth consent; Vea Health's semaglutide product page.
S2NOT VERIFIEDThe payment-sequence question did not resolve from the published material. The product sequence lists order and online intake together before clinician review. The terms describe pre-authorization with final charging after approval for certain orders, without establishing that sequence for every product. The check is open.Source: Vea Health's semaglutide product page; Vea Health's terms and conditions.
S3PASSThe telehealth consent names Foothills Professional Pharmacy, Striker Pharmacy, Emerald Compounding Pharmacy, EPIQ Scripts and DiRx Health as prescription fulfillment partners.Source: Vea Health's telehealth consent.
S4PASSThe home page and telehealth consent state that compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness or quality.Source: Vea Health's website; Vea Health's telehealth consent.
S5FAILProduct pages claim triple testing and batch purity, potency and sterility checks without providing a reachable certificate of analysis or lot document.Source: Vea Health's semaglutide product page; Vea Health's tirzepatide product page.
S6PASSThe privacy page and telehealth consent list Vea Health, Inc. at 1111B S Governors Ave STE 92678, Dover, DE 19904.Source: Vea Health's privacy policy; Vea Health's telehealth consent.
S7FAILThe semaglutide and tirzepatide product pages require a plan selection to see treatment pricing. The visible $1,080 figure is an asserted value for included app access, not the medication price.Source: Vea Health's semaglutide product page; Vea Health's tirzepatide product page.
S8PASSNo FDA warning letter names Vea Health, Vea Health Inc. or Dr Telx, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+.

Visit Vea Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.